Key Drivers
- Profitability rebound
- Solid liquidity
- High leverage
AIAI Summary
EVO should be viewed less as a platform-growth compounder and more as an execution-driven turnaround, because while partnership wins confirm franchise value, delayed monetization and a weaker 2026 outlook mean the key investment test is whether those collaborations can convert into sustained revenue, positive EBITDA, and real cash flow before the balance sheet and market patience run out.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability rebound
- •Solid liquidity
- •High leverage
EVO showed a sharp profitability turnaround in Q2 2026 with stronger margins and operating profit, but elevated leverage, heavy intangibles, and weak cash generation continue to temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Range-bound base
- •Failed breakout
- •Support holding
EVO has been range-bound over the last month, holding $1.91-$1.95 support but failing to sustain its breakout above $2.00-$2.19, so it needs to reclaim $2.00-$2.10 to confirm strength while a break below $1.91 would weaken the setup.
Brief push to $2.19 on
Sentiment & News
Key News Insights:
- •AI Collaboration
- •Preclinical Win
- •Hold Sentiment
Evotec is expanding partnerships and outsourcing wins, but sentiment stays cautious with a consensus Hold and a $3.00 target.
The updates are operationally supportive, but the stock may remain range-bound until analyst sentiment improves
Similar Companies in Healthcare
Other companies in the same sector with AI ratings